exual problems. Nurses need to be the initiators of these sensitive conversations to put patients at ease and work together to implement positive measures to reduce the sexuality-related issues patients face.Oral dysaesthesia is a condition characterised by persistent alteration to oral sensation, perceived by the patient to be abnormal and unpleasant, in the absence of mucosal pathology. Its aetiology remains uncertain. The condition was attributed as a psychosomatic disease for much of the 20th century, but with newer technologies, recent literature has mostly focused on a possible peripheral or central neuropathic aetiology to oral dysaesthesia. Despite this, psychotropic medications and psychological treatments remain forefront in the armamentarium for the management of oral dysaesthesia. This article aims to review the literature surrounding the pathogenesis of oral dysaesthesia and explore whether oral dysaesthesia is a somatic symptom disorder.Aims To investigate the genetic etiology and evaluate the diagnostic application of next-generation sequencing for diabetes/persistent hyperglycemia in children and adolescents. Materials and methods Patients with diabetes/persistent hyperglycemia, presenting with at least one other clinical manifestation (other than diabetes), or with a family history of diabetes, were recruited. The clinical and laboratory characteristics of the patients were recorded. Next-generation sequencing (NGS) was performed, and candidate variants were verified by Sanger sequencing. Variant pathogenicity was further evaluated according to the American College of Medical Genetics and Genomics guidelines. Results This study included 101 potential probands, 36 of whom were identified as positive by genetic testing. A further 51.2% and 20.9% of variants were determined to be pathogenic or likely pathogenic, respectively. Variants associated with the disease were primarily identified in 21 genes and three regions of copy number variants. Among the 39 variants in 21 genes, 61.5% (24/39) were novel. The genetic diagnosis of 23 cases was confirmed based on genetic evidence and associated clinical manifestations. We reported GCK variants (21.7%, 5/23) as the most common etiology in our cohort. Different clinical manifestations were observed in one family with WFS1 variants. click here Conclusions Our findings support the use of NGS as a standard method in patients with diabetes/persistent hyperglycemia and provide insights into the etiologies of these conditions.Objective To develop a model and methodology for predicting the risk of Gleason upgrading in prostate cancer active surveillance (AS) patients, and using the predicted risks to create risk-based personalized biopsy schedules as an alternative to one-size-fits-all schedules (e.g., annually). Furthermore, to assist patients and doctors in making shared decisions of biopsy schedules, by providing them quantitative estimates of the burden and benefit of opting for personalized versus any other schedule in AS. Last, to externally validate our model and implement it along with personalized schedules in a ready to use web-application. Materials and methods Repeat prostate-specific antigen (PSA) measurements, timing and results of previous biopsies, and age at baseline from the world's largest AS study, Prostate Cancer Research International Active Surveillance or PRIAS (7813 patients, 1134 experienced upgrading). We fitted a Bayesian joint model for time-to-event and longitudinal data to this dataset. We then validae prediction error was moderate (0.1-0.2) in GAP3 cohorts where the impact of PSA value and velocity on upgrading-risk was similar to PRIAS, but large (0.2-0.3) otherwise. Our model required recalibration of baseline upgrading-risk in validation cohorts. We implemented the validated models and the methodology for personalized schedules in a web-application (http//tiny.cc/biopsy). Conclusions We successfully developed and validated a model for predicting upgrading-risk, and providing risk-based personalized biopsy decisions, in prostate cancer AS. Personalized prostate biopsies are a novel alternative to fixed one-size-fits-all schedules that may help to reduce unnecessary prostate biopsies while maintaining cancer control. The model and schedules made available via a web-application enable shared decision making of biopsy schedules by comparing fixed and personalized schedules on total biopsies and expected time delay in detecting upgrading.Serum high-molecular-weight adiponectin (HMWA) has a positive correlation with insulin secretion in a Japanese population. To validate this correlation, we investigated the correlation between serum HMWA and proinsulin, a marker of beta-cell dysfunction, in this population. 488 participants (53.9% females) aged 35 to 79 years without having oral hypoglycemic agents and/or insulin were enrolled. HMWA was significantly and inversely correlated with proinsulin adjusted for age and sex (partial regression coefficient β= -0.37; 95% confidence interval -0.46 to -0.28). When the participants were divided into two groups by median values of body mass index (23.2 kg/m2 ), serum insulin (4.3 µU/mL), or homeostasis model assessment of insulin resistance (1.0), similar inverse correlations were observed adjusted for age and sex in both groups. Our results demonstrated that the HMWA level was inversely correlated with the proinsulin level in a general Japanese population.Liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) receive a higher proportion of livers from donation after circulatory death (DCD) donors compared to non-HCC etiologies. Nevertheless, data on outcomes in patients with HCC receiving DCD grafts are limited. We aimed to evaluate the influence of DCD livers on post- LT outcome among HCC patients. We identified 7,563 patients in the UNOS database who underwent LT with MELD exception from 2012-2016, including 567 (7.5%) who received a DCD donor and 6996 (92.5%) who received a donation after brain death (DBD) donor. Kaplan-Meier probabilities of post-LT HCC recurrence at 3 years were 7.6% for DCD and 6.4% for DBD (p=0.67) and post-LT survival at 3-years was 81% vs 85%, respectively (p=0.008). On multivariable analysis, DCD (HR 1.38, p=0.005) was an independent predictor of post-LT mortality. However, a survival difference post-LT was only observed in subgroups at higher risk for HCC recurrence including RETREAT score ≥4 (DCD 57% versus DBD 73%, p=0.